Loading…
Sana Biotechnology, Inc. is projected to rise to $3.09 by 2027, a +1% move from its current price of $3.06. SANA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $2.98 | $3.06 | $3.14 | 0.00% |
| May 30 | $2.94 | $3.06 | $3.18 | -0.01% |
| May 31 | $2.92 | $3.06 | $3.21 | -0.01% |
| Jun 1 | $2.90 | $3.06 | $3.23 | -0.02% |
| Jun 2 | $2.88 | $3.06 | $3.25 | -0.02% |
| Jun 3 | $2.86 | $3.06 | $3.27 | -0.03% |
| Jun 4 | $2.85 | $3.06 | $3.29 | -0.03% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.85 | $3.06 | $3.29 | -0.03% |
| Week 2 | $2.76 | $3.06 | $3.39 | -0.07% |
| Week 3 | $2.70 | $3.06 | $3.46 | -0.10% |
| Week 4 | $2.65 | $3.06 | $3.53 | -0.13% |
| Week 5 | $2.60 | $3.05 | $3.59 | -0.17% |
| Week 6 | $2.56 | $3.05 | $3.64 | -0.20% |
| Week 7 | $2.52 | $3.05 | $3.69 | -0.23% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines in the United States.
It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.
Its product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells.
The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes.
Sana Biotechnology, Inc. (SANA) is a biotechnology company in the Healthcare category focused on engineered cells as medicines.
The current price is $3.07 and the market capitalization stands at $854.36M. The stock is ranked 2648 by market cap among listed assets.
Near-term price activity is framed by a bearish technical stance, but the forecast horizon shows potential upside over time, with multi-year targets extending into the mid/high single digits and beyond.
Forecasts illustrate a trajectory where the avg price progresses from roughly the current level toward higher levels by 2030, 2040, and 2050, with 2030 avg $3.17 and max $4.68, 2040 avg $5.97 and max $10.28, and 2050 avg $9.29 and max $17.57.
A major floor 17.4% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.7% away) — a key level to hold.
The nearest ceiling, 24.8% above — a clean break opens room to run.
A major ceiling 63.4% above — clearing it would confirm fresh momentum.
Key SANA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SANA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.09 | Sell | $3.08 | Sell |
| MA 10 | $3.09 | Sell | $3.13 | Sell |
| MA 20 | $3.26 | Sell | $3.21 | Sell |
| MA 50 | $3.24 | Sell | $3.34 | Sell |
| MA 100 | $3.69 | Sell | $3.54 | Sell |
| MA 200 | $3.86 | Sell | $3.66 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.88 | Neutral |
| Stoch RSI (14) | 12.88 | Buy |
| CCI (20) | -80.79 | Neutral |
| Williams %R (14) | -96.15 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -12.82 | Sell |
| Bollinger %B (20,2) | 0.24 | Neutral |
| Stochastic %K (14) | 3.85 | Buy |
| TRIX (15) | -0.22 | Sell |
| Awesome (5,34) | -0.24 | Sell |
| Ultimate (7,14,28) | 38.86 | Neutral |
| Momentum (10) | -0.20 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 3.07 | Sell |
| ADX (14) | 14.81 | Neutral |
| ATR (14) | 0.08 | Info |
The 30-day technical picture is bearish, with RSI14 at 40 and the price trading beneath the 50-day simple moving average (SMA50) of $3.25 while the 200-day simple moving average (SMA200) sits at $3.86.
Near-term support is at $3.04 and resistance at $3.82, framing a tight range around the current price. The 30-day price range spans from a low of $2.54 to a high of $3.71, highlighting modest upside within the current channel.
The stock also shows elevated volatility, with annualized volatility at 60%, underscoring substantial upside and downside risk for short-term holders.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.68 | $3.06 | $4.03 | 0% | Neutral | |
| $2.45 | $3.09 | $4.13 | +1% | Neutral | |
| $2.48 | $3.21 | $4.44 | +5% | Neutral | |
| $2.28 | $3.02 | $4.29 | -1% | Neutral | |
| $2.36 | $3.18 | $4.64 | +4% | Neutral | |
| $2.64 | $3.63 | $5.40 | +19% | Neutral | |
| $2.75 | $3.84 | $5.83 | +26% | Bullish | |
| $3.00 | $4.27 | $6.58 | +39% | Bullish | |
| $3.08 | $4.45 | $6.97 | +45% | Bullish | |
| $2.92 | $4.28 | $6.80 | +40% | Bullish | |
| $3.82 | $5.99 | $10.12 | +96% | Bullish | |
| $5.37 | $9.42 | $17.40 | +208% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.68 | $3.06 | $3.58 | +0.00% |
| June 2026 | $2.55 | $2.99 | $3.59 | -2.28% |
| July 2026 | $2.57 | $3.05 | $3.71 | +1.89% |
| August 2026 | $2.55 | $3.04 | $3.74 | -0.20% |
| September 2026 | $2.50 | $2.99 | $3.71 | -1.65% |
| October 2026 | $2.55 | $3.07 | $3.84 | +2.71% |
| November 2026 | $2.64 | $3.19 | $4.01 | +3.81% |
| December 2026 | $2.62 | $3.18 | $4.03 | -0.30% |
Click any year to see its month-by-month SANA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Sana Biotechnology, Inc.'s 2026 outlook centres on $3.06, within a $2.68 to $4.03 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, SANA could reach as high as $4.13, with a base case around $3.09 and support toward $2.45 — roughly +1% from $3.06. A consolidation phase looks the most probable path here.
Expect SANA to range from $2.48 to $4.44 through 2028. The $3.21 average target implies a +5% move from current prices. That is up +4% on the projected 2027 average. Price action looks broadly range-bound.
The SANA price prediction for 2029 points to an average of $3.02 (low $2.28, high $4.29) — a potential decline of -1% on today's $3.06. A consolidation phase looks the most probable path here.
In 2030, SANA is projected to trade between $2.36 and $4.64, averaging $3.18 — a potential gain of +4% from today's $3.06. That is up +6% on the projected 2029 average. Price action looks broadly range-bound.
Sana Biotechnology, Inc.'s 2031 outlook centres on $3.63, within a $2.64 to $5.40 range. That is up +14% on the projected 2030 average. That marks a +19% change versus current levels. A consolidation phase looks the most probable path here.
By 2032, SANA could reach as high as $5.83, with a base case around $3.84 and support toward $2.75 — roughly +26% from $3.06. Momentum favours further upside here.
Expect SANA to range from $3.00 to $6.58 through 2033. The $4.27 average target implies a +39% move from current prices. That is up +11% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The SANA price prediction for 2034 points to an average of $4.45 (low $3.08, high $6.97) — a potential gain of +45% on today's $3.06. Momentum favours further upside here.
In 2035, SANA is projected to trade between $2.92 and $6.80, averaging $4.28 — a potential gain of +40% from today's $3.06. That is -4% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
Sana Biotechnology, Inc.'s 2040 outlook centres on $5.99, within a $3.82 to $10.12 range. That is up +40% on the projected 2035 average. That marks a +96% change versus current levels. Momentum favours further upside here.
By 2050, SANA could reach as high as $17.40, with a base case around $9.42 and support toward $5.37 — roughly +208% from $3.06. Buyers look set to stay in control over this stretch.
Investing $1,000 in SANA today (≈ 326.797386 SANA) could be worth
$3,079.4
+$2,079.4 (+208%) by 2050 · US Dollar
Based on the average projected SANA price of $9.42 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SANAwould be worth at today's price.
$1,000 invested in SANA on May 27, 2025 (≈ 500 SANA) would be worth
$1,530
+$530 (+53.0%) today · 1.53× · US Dollar
Based on a SANA entry price of $2 vs. today's $3.06.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.11 | $983.92 | -1.6% |
| 1 month ago | $3.26 | $938.65 | -6.1% |
| 3 months ago | $4.27 | $716.63 | -28.3% |
| 6 months ago | $4.3 | $711.63 | -28.8% |
| 1 year ago | $2 | $1,530 | +53.0% |
| All time (5.0y) ago | $21.13 | $144.82 | -85.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SANA forecast.
Our base-case forecast reaches $6.10 around 2050.
Implied market cap at $6.10: $1.7B
Over the multi-year forecast, Sana shows a gradual escalation in average price with notable upside in later years. The 2030 forecast places the average at $3.17 with a max of $4.68, while the 2040 projection climbs to an average of $5.97 and a max of $10.28, and the 2050 view reaches an average of $9.29 with a max of $17.57. These figures align with a shift from neutral to bullish sentiment beginning around 2032, and culminate in stronger upside by 2040 and beyond, with ROI peaking at 94.3% in 2040 and 202.8% in 2050.
The longer-term outlook carries considerable upside potential but also notable risk, given the 60% annualized volatility. While the later-year forecasts show meaningful gains, these are estimates and not guarantees, and actual results will depend on a range of factors affecting the biotechnology sector and Sana’s development programs.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $3.17, with a minimum of $2.32 and a maximum of $4.68; the projected ROI is 3.2%.
Forecasts suggest neutral to bullish momentum over time, with the average price rising to $3.62 in 2031 and $3.81 in 2032, and significant upside in 2040 (average $5.97, max $10.28) and 2050 (average $9.29, max $17.57), though outcomes are not guaranteed and depend on multiple factors.
Yes. The 2040 forecast lists a max of $10.28, and the 2050 forecast lists a max of $17.57, indicating that the price could exceed $10 in the outlook period.
Current price is $3.07 and market capitalization is $854.36M.
The asset exhibits high volatility, with annualized volatility at 60%.
Sana Biotechnology, Inc. Community Discussion
0Share your Sana Biotechnology, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.